OBJECTIVES: Depression is prevalent in inflammatory bowel disease (IBD) patients. The impact of depression on IBD is not well-studied. It is unknown how providers should assess depression. METHODS: We used data from the Sinai-Helmsley Alliance for Research Excellence cohort, to assess methods of diagnosing depression and effects of baseline depression on disease activity at follow-up. A patient health questionnaire (PHQ-8) score ≥5 was consistent with mild depression. Relapse was defined as a modified Harvey-Bradshaw Index ≥5 or Simple Clinical Colitis Activity Index >2. We performed binomial regression to calculate adjusted risk ratios (RRs). RESULTS: We included 2,798 Crohn's disease (CD) patients with 22-month mean follow-up and 1,516 ulcerative colitis (UC) patients with 24-month mean follow-up. A total of 64% of CD patients and 45% of UC patients were in remission at baseline. By self-report, 20% of CD and 14% of UC patients were depressed. By PHQ-8, 38% of CD and 32% of UC patients were depressed (P<0.01). Adjusted for sex, remission, and disease activity, CD patients with baseline depression were at an increased risk for relapse (RR: 2.3; 95% confidence interval (CI): 1.9-2.8), surgery, or hospitalization (RR: 1.3 95% CI: 1.1-1.6) at follow-up. UC patients with baseline depression were also at increased risk for relapse (RR: 1.3; 95% CI: 0.9-1.7), surgery, or hospitalization (RR: 1.3; 95% CI: 1.1-1.5) at follow-up. CONCLUSIONS: Baseline depression is associated with a higher risk for aggressive IBD at follow-up. A single question is not a sensitive method of assessing depression. Providers should consider administering the PHQ-8 to capture those at greater risk for aggressive disease.
OBJECTIVES:Depression is prevalent in inflammatory bowel disease (IBD) patients. The impact of depression on IBD is not well-studied. It is unknown how providers should assess depression. METHODS: We used data from the Sinai-Helmsley Alliance for Research Excellence cohort, to assess methods of diagnosing depression and effects of baseline depression on disease activity at follow-up. A patient health questionnaire (PHQ-8) score ≥5 was consistent with mild depression. Relapse was defined as a modified Harvey-Bradshaw Index ≥5 or Simple Clinical Colitis Activity Index >2. We performed binomial regression to calculate adjusted risk ratios (RRs). RESULTS: We included 2,798 Crohn's disease (CD) patients with 22-month mean follow-up and 1,516 ulcerative colitis (UC) patients with 24-month mean follow-up. A total of 64% of CDpatients and 45% of UC patients were in remission at baseline. By self-report, 20% of CD and 14% of UC patients were depressed. By PHQ-8, 38% of CD and 32% of UC patients were depressed (P<0.01). Adjusted for sex, remission, and disease activity, CDpatients with baseline depression were at an increased risk for relapse (RR: 2.3; 95% confidence interval (CI): 1.9-2.8), surgery, or hospitalization (RR: 1.3 95% CI: 1.1-1.6) at follow-up. UC patients with baseline depression were also at increased risk for relapse (RR: 1.3; 95% CI: 0.9-1.7), surgery, or hospitalization (RR: 1.3; 95% CI: 1.1-1.5) at follow-up. CONCLUSIONS: Baseline depression is associated with a higher risk for aggressive IBD at follow-up. A single question is not a sensitive method of assessing depression. Providers should consider administering the PHQ-8 to capture those at greater risk for aggressive disease.
Authors: Eva M Szigethy; Ada O Youk; David Benhayon; Diane L Fairclough; Melissa C Newara; Margaret A Kirshner; Simona I Bujoreanu; Christine Mrakotsky; Athos Bousvaros; Arvind I Srinath; David J Keljo; David J Kupfer; David R DeMaso Journal: J Pediatr Gastroenterol Nutr Date: 2014-05 Impact factor: 2.839
Authors: Divya Keerthy; Ada Youk; Arvind I Srinath; Nasuh Malas; Simona Bujoreanu; Athos Bousvaros; David Keljo; David R DeMaso; Eva M Szigethy Journal: J Pediatr Gastroenterol Nutr Date: 2016-12 Impact factor: 2.839
Authors: Christian Mittermaier; Clemens Dejaco; Thomas Waldhoer; Anna Oefferlbauer-Ernst; Wolfgang Miehsler; Markus Beier; Wolfgang Tillinger; Alfred Gangl; Gabriele Moser Journal: Psychosom Med Date: 2004 Jan-Feb Impact factor: 4.312
Authors: Kurt Kroenke; Tara W Strine; Robert L Spitzer; Janet B W Williams; Joyce T Berry; Ali H Mokdad Journal: J Affect Disord Date: 2008-08-27 Impact factor: 4.839
Authors: Min Chul Kim; Yoon Suk Jung; Young Seok Song; Jung In Lee; Jung Ho Park; Chong Il Sohn; Kyu Yong Choi; Dong Il Park Journal: Gut Liver Date: 2016-05-23 Impact factor: 4.519
Authors: Miguel Regueiro; Benjamin Click; Alyce Anderson; William Shrank; Jane Kogan; Sandra McAnallen; Eva Szigethy Journal: Clin Gastroenterol Hepatol Date: 2018-04-12 Impact factor: 11.382
Authors: Erin M Kim; Cara Randall; Renee Betancourt; Staci Keene; Amy Lilly; Mark Fowler; Evan S Dellon; Hans H Herfarth Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325
Authors: Nisha B Shah; Jennifer Haydek; James Slaughter; Jonathan R Ashton; Autumn D Zuckerman; Rochelle Wong; Francesca Raffa; Ailish Garrett; Caroline Duley; Kim Annis; Julianne Wagnon; Lawrence Gaines; Robin Dalal; Elizabeth Scoville; Dawn B Beaulieu; David Schwartz; Sara N Horst Journal: Inflamm Bowel Dis Date: 2020-01-06 Impact factor: 5.325
Authors: Sarah Rizwan Qazi; Muhammad Irfan; Zoobia Ramzan; Muhammad Jahanzaib; Maleeha Zaman Khan; Mahrukh Nasir; Muhammad Shakeel; Ishtiaq Ahmad Khan Journal: Mol Biol Rep Date: 2022-01-18 Impact factor: 2.316
Authors: Ruth Ann Marrie; Lesley A Graff; John D Fisk; Scott B Patten; Charles N Bernstein Journal: Inflamm Bowel Dis Date: 2021-07-27 Impact factor: 5.325
Authors: Jonathan Blackwell; Christopher Alexakis; Sonia Saxena; Hanna Creese; Alex Bottle; Irene Petersen; Matthew Hotopf; Richard C G Pollok Journal: BMJ Open Gastroenterol Date: 2021-05